Elucid Bio is a Boston-based medical technology company using AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease.
Patients with psoriasis treated with biologic therapy, which are protein-based infusions to suppress inflammation, had a significant reduction in Lipid-Rich Necrotic Core plaque in coronary arteries over one year, as measured by vascuCAP. The research was published in Circulation: Cardiovascular Imaging, an American Heart Association journal.
It’s one of the most intractable areas of focus in all of vascular disease, and the source of—inarguably, Brajesh K. Lal, MD, emphasizes—the most intensely studied vascular surgical procedure anywhere in the sphere of the specialty. And for some years, Lal has had the development of a more accurate method of risk assessment for this perennial vascular problem fixed firmly in his sights: carotid disease.